First Trust Advisors
NRIX icon

First Trust Advisors’s Nurix Therapeutics NRIX Stock Holding History

First Trust Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.75M Buy
+360,848
New +$6.15M 0.01% 1272
2025
Q1 		– Sell
-135,903
Closed -$2.56M – 2595
2024
Q4 		$2.56M Buy
+135,903
New +$3.12M ﹤0.01% 1701

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors's NRIX Position: Q2 2026 in Review

First Trust Advisors opened a new position in Nurix Therapeutics (NRIX) in Q2 2026: 360,848 shares worth $8.75M. The stake represents 0.01% of the portfolio and ranks #1272 among its holdings. This is a return to the name: First Trust Advisors previously reported a position in NRIX as recently as Q4 2024.

First Trust Advisors first reported a position in NRIX in Q4 2024 and has held it in 2 quarters since. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • First Trust Advisors held 360,848 shares of Nurix Therapeutics worth $8.75M as of Q2 2026.
  • Nurix Therapeutics was a new First Trust Advisors position in Q2 2026.
  • Nurix Therapeutics made up 0.01% of First Trust Advisors's portfolio in Q2 2026, its #1272 holding.
  • First Trust Advisors first reported a position in Nurix Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.